Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Memphis-based biotech GTx has initiated a pivotal phase III clinical trial for Acapodene for the prevention of prostate cancer in high risk men.
Subscribe to our email newsletter
The pivotal phase III trial is a double blind, placebo controlled, multicenter study. Patients with high grade prostatic intraepithelial neoplasia (PIN), the precancerous lesion in prostate cancer, will be randomized into two treatment groups: 20mg toremifene or placebo. The primary endpoint of the clinical trial is the incidence of prostate cancer.
GTx has received initial comments from the FDA on the preliminary review of the Special Protocol Assessment (SPA). As part of the SPA process, GTx plans to address these comments and resubmit the revised SPA.